Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Elderly NSC lung cancer patients benefit from concurrent chemoradiation

Fit older adults with locally advanced non-small-cell lung cancer reap similar benefit from concurrent chemoradiation with etoposide and cisplatin as younger patients, but experience higher rates of hospitalization and toxicity, research shows.

8 Aug 2012

Folate, excision biomarkers not predictive for small-cell lung cancer response

Biomarkers associated with the folate metabolism and excision repair pathways are not sufficiently prognostic to aid chemotherapy decisions for patients with extensive-stage disease small-cell lung cancer, results of a phase III trial show.

8 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Six hospitals join CoC ProvenCare Lung Cancer Collaborative

Six more hospitals have joined a national pilot study already under way to promote evidence-based evaluation and treatment standards for patients with non-small cell lung cancer (NSCLC). Patients with this type of lung cancer are also candidates for an operation called "lung resection."

2 Aug 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

24 Jul 2012

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

23 Jul 2012

NSCLC survival increase 'an artifact of PET assessment'

There has been no increase in survival among non-small-cell lung cancer patients in recent years, with evidence suggesting otherwise likely due to positron emission tomography-induced stage migration and selection bias, say US scientists.

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

A Marshall University faculty member has been awarded a three-year, $426,000 grant by the National Institutes of Health (NIH) to further her lung cancer research.

21 Jul 2012

MSU nursing researcher’s Wii-Fit program helps lung cancer patients reduce fatigue

With the support of a $379,741 grant from the National Cancer Institute and the Nintendo Wii game system, nursing researcher Amy Hoffman aims to help lung cancer patients reduce fatigue and get more exercise as they transition from the hospital to the home after surgery.

17 Jul 2012

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

ACR updates 39 appropriateness criteria topics and adds five new criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

29 Jun 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

Small Cell Lung Cancer News and Research

Elderly NSC lung cancer patients benefit from concurrent chemoradiation

Folate, excision biomarkers not predictive for small-cell lung cancer response

GTx reports revenue of $1.6 million for second quarter 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Six hospitals join CoC ProvenCare Lung Cancer Collaborative

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Potential biomarker to predict lung cancer patients' response to chemotherapy

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

NSCLC survival increase 'an artifact of PET assessment'

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

MSU nursing researcher’s Wii-Fit program helps lung cancer patients reduce fatigue

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

ACR updates 39 appropriateness criteria topics and adds five new criteria

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News